Jul 6, 2020

Proceedings from an independent satellite symposium during the Society of Gynecologic Oncology’s 2020 Annual Meeting on Women’s Cancer Webinar Series. Featuring perspectives from Drs Robert L Coleman, Stephanie Lheureux, Joyce F Liu and Kathleen Moore.

• Considerations for the use of a PARP inhibitor as a component of up-front treatment for patients with ovarian cancer (OC) (00:00)
• Selection of mutation assay for patients with newly diagnosed OC (5:27)
• PARP inhibitor maintenance therapy for newly diagnosed OC; recently FDA-approved options (13:55)
• Integration of PARP inhibitor monotherapy or combination with bevacizumab into maintenance therapy for newly diagnosed OC (24:47)
• Can homologous recombination deficiency testing guide therapeutic decision-making for patients with OC? (34:20)
• Treatment approach for patients who experience disease progression on a PARP inhibitor; potential role of switching to another PARP inhibitor (40:04)
• Clinical care of patients who receive a PARP inhibitor and experience side effects or other tolerability issues requiring dose adjustment or discontinuation (44:24)
• “Manage Wisely: PARP inhibitor treatment and adverse events” (53:17)
• Design, efficacy and safety findings from the Phase III VELIA trial evaluating veliparib in combination with carboplatin and paclitaxel and as continuation maintenance therapy for newly diagnosed advanced OC; implications for clinical practice (58:47)
• Choice of PARP inhibitor for patients with platinum-sensitive OC (1:08:08)
• ASCO 2020 Abstract 6002: Final overall survival results from SOLO2/ENGOT-ov21: A Phase III trial assessing maintenance olaparib in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation (1:15:06)

CME information and select publications